Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Assess the Efficacy, Safety and Tolerability of ASP0367 in Participants With Primary Mitochondrial Myopathy
Conditions
Interventions
Bocidelpar
Placebo
Locations
11
United States
University of California, San Diego
La Jolla, California, United States
Stanford University Medical Center
Stanford, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Columbia University Irving Medical Center
New York, New York, United States
Akron Children's Hospital
Akron, Ohio, United States
Start Date
May 24, 2021
Primary Completion Date
May 8, 2024
Completion Date
May 8, 2024
Last Updated
July 3, 2025
Lead Sponsor
Astellas Pharma Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions